Figure 3.

BO-Ms increase drainage efficiency of meningeal lymphatic for uptake of cerebrospinal fluid. (A) Schematic of the experimental layout where mice were injected ICG-NPs and then intragastrical administration (i.g.) of saline or BO-Ms, the dCLNs were monitored at different time points by the near-infrared fluorescence imaging system of DPM. (B) Representative fluorescence imaging and (C) intensity of ICG-NPs in mice left and right dCLNs in both groups after ICG-NPs injected in lateral ventricle. **p < 0.01, ***p < 0.001 (Student's t-test), n = 3 mice per group, representative of two independent experiments. Data are means ± SEM. (D) Representative fluorescence imaging and (E) intensity of ICG-NPs in left and right dCLNs in control and BO-Ms groups after ICG-NPs injected in the hippocampus. **p < 0.01, ***p < 0.001 (Student's t-test), n = 3 mice per group, representative of two independent experiments. Data are means ± SEM. (F) Schematic of the experiments that mice were injected in intra-cisterna magna (i.c.m.) with EB, and then the saline or BO-Ms was orally administered in order to measure drainage into meningeal lymphatic vessels. (G) Distribution of EB in meningeal lymphatics in control and BO-Ms group. White narrows: EB. (H) Representative meninges stained with anti-LYVE-1 (CY3-conjugated secondary antibody, immunofluorescence) and AF488-conjugated anti-LYVE-1 (i.c.m.) distribution in the meningeal lymphatic vessels of the control group and BO-Ms group at 30 min. (Scale bars, 3 mm). (I) The coverage rate of AF488-conjugated anti-LYVE-1 antibody (percentage of meninges). *p < 0.05 (one-way ANOVA with Student's t-test), n = 3 mice per tissue, representative of two independent experiments. Data are means ± SEM.